Signing Ceremony for Memorandum of Understanding Held between Nagasaki University and International Vaccine Institute

　On March 7, 2024, Nagasaki University and the International Vaccine Institute (IVI) signed a Memorandum of Understanding (MOU) for vaccine research and development at the IVI headquarters in Seoul, Korea.

　IVI is an international organization established in 1997 in Seoul through an agreement between the United Nations Development Program (UNDP) and the Korean government. The IVI works to discover, develop, and provide safe, effective, and affordable vaccines to improve public health worldwide.

ⅤNagasaki University also has a long history in infectious disease research. In 2022, the university established the "DEJIMA Infectious Diseases Research Alliance (DIDA)" to facilitate the integrated management of research resources related to infectious diseases within the university. It is also designated as one of the “Japan Initiative for World-leading Vaccine Research and Development Centers," managed by the Japan Agency for Medical Research and Development (AMED).

　As previously stated, Nagasaki University and IVI share many similarities in vaccine research and development, and collaboration is expected to lead to great synergy.

　During the signing ceremony, President Nagayasu of Nagasaki University and IVI Director Dr. Jerome Kim signed the MOU. Professors Morita and Yamamoto, respectively the Director and Deputy Director of DIDA, and Professor Kaneko, Director of International Clinical Development at DIDA, attended the ceremony along with IVI executives and researchers. The two institutions gave introductory presentations, held discussions, and established a cooperative relationship for future collaboration.

List